Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277592 | 0.81 | CA2 (0.45) | CA2CA1SMN1; SMN2CYP2A6CA12 | |
| SCHEMBL13780476 | 0.78 | CA1 (0.56) | CA2CA1SMN1; SMN2CYP2A6CA12 | |
| SCHEMBL4603299 | 0.76 | CA2 (0.54) | CA2CA1SMN1; SMN2CYP2A6CA12 | |
| SCHEMBL4273616 | 0.73 | CA2 (0.62) | CA2CA1SMN1; SMN2CA12CA9 | |
| SCHEMBL21400131 | 0.71 | CYP2A6 (0.54) | CA2CA1SMN1; SMN2CYP2A6ALDH1A1 | |
| SCHEMBL1233284 | 0.71 | CYP2A6 (0.63) | CA2CA1SMN1; SMN2CYP2A6TAAR1 | |
| SCHEMBL13489638 | 0.69 | CYP2A6 (0.61) | CA2CA1SMN1; SMN2CYP2A6CA12 | |
| SCHEMBL3070140 | 0.69 | CYP2A6 (0.61) | CA2CA1SMN1; SMN2CYP2A6TAAR1 | |
| SCHEMBL29425310 | 0.69 | CA2 (1.00) | CA2CA1CYP2A6CA12CA4 | |
| SCHEMBL4243562 | 0.69 | CA2 (1.00) | CA2CA1CYP2A6CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249828-A1 | PREPARATION OF SULFAMIDE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089235-A1 | PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | STS, SULT2A1, SULT1A1 | CA2 1316/4885CA1 449/4885SMN1; SMN2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.